METHODS FOR THE TREATMENT OF SOLID TUMOR CANCERS USING ILLUDINS AND BIOMARKERS
作者： Kulkami Aditya , Vedaraju Yuvanesh , Kathad Umesh , Asaithambi Arun
DOI:
关键词:
摘要: Methods for determining the likelihood that a subject suffering from solid tumor cancer will benefit treatment with an illudin are disclosed herein. Further, there also methods based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta- Hydroxylase (ASPH) together one or more genes alone may be used to enhance guide illudin. certain protein gene expressed methylated.
lens.org 参考文章(5)
Michael Kelner, Affinity medicant conjugate ,(2015)
Kathryn E. Pietsch, Paul M. van Midwoud, Peter W. Villalta, Shana J. Sturla, Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities. Chemical Research in Toxicology. ,vol. 26, pp. 146- 155 ,(2013) , 10.1021/TX300430R
Michael J. Kelner, Trevor C. Mcmorris, Illudin analogs useful as anticancer agents ,(2006)
Steen Knudsen, Methods for predicting drug responsiveness in cancer patients ,(2016)
Offit Kenneth, Topka Sabine, Joseph Vijai, DIAGNOSIS & TREATMENT OF ERCC3-MUTANT CANCER ,(2018)